

Myasthenia Gravis Panel 2

Order Name: **ACETY BBM**

Test Number: 5500250

Revision Date: 01/01/2024

| TEST NAME | METHODOLOGY | LOINC CODE |
|--|----------------|------------|
| Acetylcholine Receptor Binding Antibody | See Test Notes | 11034-6 |
| Acetylcholine Receptor Blocking Antibody | See Test Notes | 11561-8 |
| Acetylcholine Receptor Modulating Antibody | Flow cytometry | 30192-9 |

SPECIMEN REQUIREMENTS

| Specimen | Specimen Volume (mL) | Specimen Type | Specimen Container | Transport Environment |
|--------------|--|---------------|----------------------------------|-----------------------|
| Preferred | 2 mL (1.5) | Serum | Clot Activator SST | Refrigerated |
| Alternate 1 | 2 mL (1.5) | Serum | Clot Activator (Red Top, No-Gel) | Refrigerated |
| Instructions | Separate serum from cells ASAP or within 2 hours of collection Unacceptable Conditions: Contaminated, hemolyzed, or severely lipemic specimens. Stability After separation from cells: Ambient: 2 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles) | | | |

GENERAL INFORMATION

| | |
|------------------|--|
| Testing Schedule | Sun-Sat |
| Expected TAT | 4-6 Days |
| Clinical Use | Myasthenia Gravis is a neurological disorder characterized by a decrease in acetylcholine receptors. Patients exhibit skeletal muscle weakness and fatigability. Approximately 80% of patients with Myasthenia Gravis, excluding ocular involvement only, have detectable acetylcholine receptor antibody. |
| CPT Code(s) | 86041, 86042, 86043 |
| Lab Section | Reference Lab |